5-Azacytidine is primarily used in the treatment of myelodysplastic syndromes (MDS), a group of cancers where the bone marrow does not produce enough healthy blood cells. It works by inhibiting DNA methylation, which helps to restore normal function to genes that control cell growth and differentiation. This action can lead to improved blood cell production and reduced need for transfusions in patients. Additionally, 5-Azacytidine is being researched for its potential in treating other types of cancer, including acute myeloid leukemia (AML), due to its ability to reactivate tumor suppressor genes that have been silenced by abnormal methylation. In experimental settings, it is also explored for its role in epigenetic research, helping scientists understand how gene expression is regulated and how it can be manipulated for therapeutic purposes.